XFRA CAPITAL ADJUSTMENT INFORMATION

XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025

Das Instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY wird ex Kapitalmassnahme gehandelt am 26.08.2025
The instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY is traded ex capital adjustment on 26.08.2025

Das Instrument TRB US8964385046 TRINITY BIOTEC.ADR NEW A EQUITY wird cum Kapitalmassnahme gehandelt am 26.08.2025 und ex Kapitalmassnahme am 27.08.2025
The instrument TRB US8964385046 TRINITY BIOTEC.ADR NEW A EQUITY is traded cum capital adjustment on 26.08.2025 and ex capital adjustment on 27.08.2025

Das Instrument OND SE0009414576 ONCOPEPTIDES AB O.N. EQUITY wird cum Kapitalmassnahme gehandelt am 26.08.2025 und ex Kapitalmassnahme am 27.08.2025
The instrument OND SE0009414576 ONCOPEPTIDES AB O.N. EQUITY is traded cum capital adjustment on 26.08.2025 and ex capital adjustment on 27.08.2025

Das Instrument 7QF NO0010921232 AKER HORIZONS ASA NK 0,01 EQUITY wird ex Kapitalmassnahme gehandelt am 26.08.2025
The instrument 7QF NO0010921232 AKER HORIZONS ASA NK 0,01 EQUITY is traded ex capital adjustment on 26.08.2025

Zeitenwende! 3 Uranaktien vor der Neubewertung

Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!

Hier klicken

Zeit	Aktuelle Nachrichten
06:00	XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025	Das Instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY wird ex Kapitalmassnahme gehandelt am 26.08.2025 The instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY is traded ex capital adjustment... ► Artikel lesen
Fr	Aker Horizons ASA: Completed share capital reduction - New nominal value per share registered	FORNEBU, Norway, Aug. 22, 2025 /PRNewswire/ -- On 6 June 2025, an extraordinary general meeting of Aker Horizons ASA (the "Company") resolved to reduce the Company's share capital from NOK... ► Artikel lesen
31.07.	Aker Horizons: Nscale, Aker ASA and OpenAI to establish Stargate Norway	FORNEBU, Norway, July 31, 2025 /PRNewswire/ -- Reference is made to today's stock exchange notice from Aker ASA ("Aker") where Nscale Global Holdings Ltd. ("Nscale"), Aker and OpenAI announced... ► Artikel lesen
15.07.	Aker Horizons ASA reports 1H results
15.07.	Aker Horizons ASA: Half-year results 2025	FORNEBU, Norway, July 15, 2025 /PRNewswire/ -- Aker Horizons ASA (OSE: "AKH"), a developer of green energy and industry, today announced results for the first half of 2025. In the first... ► Artikel lesen

Zeit

Aktuelle Nachrichten

06:00

XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025

Aker Horizons ASA: Completed share capital reduction - New nominal value per share registered

FORNEBU, Norway, Aug. 22, 2025 /PRNewswire/ -- On 6 June 2025, an extraordinary general meeting of Aker Horizons ASA (the "Company") resolved to reduce the Company's share capital from NOK...
► Artikel lesen

31.07.

Aker Horizons: Nscale, Aker ASA and OpenAI to establish Stargate Norway

FORNEBU, Norway, July 31, 2025 /PRNewswire/ -- Reference is made to today's stock exchange notice from Aker ASA ("Aker") where Nscale Global Holdings Ltd. ("Nscale"), Aker and OpenAI announced...
► Artikel lesen

15.07.

Aker Horizons ASA reports 1H results

15.07.

Aker Horizons ASA: Half-year results 2025

FORNEBU, Norway, July 15, 2025 /PRNewswire/ -- Aker Horizons ASA (OSE: "AKH"), a developer of green energy and industry, today announced results for the first half of 2025. In the first...
► Artikel lesen

Zeit	Aktuelle Nachrichten
06:00	XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025	Das Instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY wird ex Kapitalmassnahme gehandelt am 26.08.2025 The instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY is traded ex capital adjustment... ► Artikel lesen
Mo	Huddly AS - Ex. subsequent repair offering today
Do	Earnings call transcript: Huddly Q2 2025 sees strong revenue growth
Do	Huddly AS - Q2 2025: Revenue growth of 45 %
Do	Huddly Q2 2025 slides: 45% revenue growth amid continued cash burn

Zeit

Aktuelle Nachrichten

06:00

XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025

Huddly AS - Ex. subsequent repair offering today

Earnings call transcript: Huddly Q2 2025 sees strong revenue growth

Huddly AS - Q2 2025: Revenue growth of 45 %

Huddly Q2 2025 slides: 45% revenue growth amid continued cash burn

Zeit	Aktuelle Nachrichten
06:00	XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025	Das Instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY wird ex Kapitalmassnahme gehandelt am 26.08.2025 The instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY is traded ex capital adjustment... ► Artikel lesen
Mo	Oncopeptides AB: Oncopeptides enters into additional guarantee commitments, rights issue fully guaranteed	THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen
Do	Oncopeptides Q2 2025 slides: 135% sales growth overshadowed by rights issue announcement
Do	Oncopeptides AB: Oncopeptides publishes Q2 report 2025	Stockholm - August 21, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2025. "This... ► Artikel lesen
30.07.	Oncopeptides AB: Oncopeptides Partners with SD Pharma to further broaden Pepaxti reach in Spain	Stockholm, July 30, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces a partnership with SD Pharma, a leading Spanish pharmaceutical... ► Artikel lesen

Zeit

Aktuelle Nachrichten

06:00

XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025

Oncopeptides AB: Oncopeptides enters into additional guarantee commitments, rights issue fully guaranteed

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND...
► Artikel lesen

Oncopeptides Q2 2025 slides: 135% sales growth overshadowed by rights issue announcement

Oncopeptides AB: Oncopeptides publishes Q2 report 2025

Stockholm - August 21, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2025. "This...
► Artikel lesen

30.07.

Oncopeptides AB: Oncopeptides Partners with SD Pharma to further broaden Pepaxti reach in Spain

Stockholm, July 30, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces a partnership with SD Pharma, a leading Spanish pharmaceutical...
► Artikel lesen

Zeit	Aktuelle Nachrichten
06:00	XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025	Das Instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY wird ex Kapitalmassnahme gehandelt am 26.08.2025 The instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY is traded ex capital adjustment... ► Artikel lesen
Do	Trinity Biotech appoints Paul Tivnan to board of directors
Do	Trinity Biotech plc: Trinity Biotech Appoints Paul Tivnan as Non-Executive Director
Mi	Trinity Biotech receives approval for offshore manufacturing of HIV test
Mi	Trinity Biotech plc: Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation	Approval Facilitates Immediate Offshored and Outsourced Manufacturing Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability... ► Artikel lesen

Zeit

Aktuelle Nachrichten

06:00

XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025

Trinity Biotech appoints Paul Tivnan to board of directors

Trinity Biotech plc: Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

Trinity Biotech receives approval for offshore manufacturing of HIV test

Trinity Biotech plc: Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation

Approval Facilitates Immediate Offshored and Outsourced Manufacturing Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability...
► Artikel lesen